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ABSTRACT
There is strong evidence supporting the role of maternal
arterial dysfunction in pregnancy-specific disorders such
as pre-eclampsia and intrauterine growth restriction. As
more work is focused towards this field, it is important
that methods and interpretation of arterial function
assessment are applied appropriately. Here, we summarize
techniques and devices commonly used in maternal health
studies, with consideration of their technical application in
pregnant cohorts. Copyright  2017 ISUOG. Published
by John Wiley & Sons Ltd.
INTRODUCTION
Arterial function is recognized as an important ‘risk
marker’ in evaluating cardiovascular disease. Several
parameters exist with which to assess localized and
global arterial function in both the clinical and research
setting. These are summarized in a consensus report of
the European Network for Non-invasive Investigation of
Large Arteries1; however, specific guidance for their use
in pregnant cohorts is lacking. Here, we outline suitable
techniques and devices for assessment of arterial function
in pregnancy and for the interpretation of results. We
also briefly summarize key studies of arterial function in
normal pregnancies and those with adverse outcome.
THE ARTERIAL SYSTEM
The arterial tree branches from the aorta, terminating in
the smallest arterioles, from which capillaries arise. Due
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to the pulsatile nature of cardiac ejection, blood pressure
and flow oscillate throughout the arterial tree.
Elasticity of the aorta, which is a large
elastin-containing vessel, plays an important role in
buffering oscillatory changes in blood pressure. Local
adjustments to vascular tone in the smooth muscle,
that predominates in smaller arteries and arterioles, also
help to regulate arterial blood flow. Common indices
of large-artery elasticity and vascular-tone regulation
include arterial stiffness, arterial-wave reflection and
endothelial function.
ARTERIAL STIFFNESS
Large arteries are important in buffering cyclical changes
in blood pressure by reducing peak pressure, maintaining
diastolic pressure and smoothing blood flow. With
increased arterial stiffening, which occurs with age,
genetic predisposition (e.g. with genes involved in the
differentiation of vascular smooth-muscle cells)2 and
pathological processes such as atherosclerosis, there is
an overall increase in pulse pressure, resulting in isolated
systolic hypertension. The repeated cyclical stress of high
pulse pressure propagates a cycle of further arterial
stiffening through fatigue fracture of the elastic elements
within the arterial wall.
Arterial stiffness can be quantified by the pulse-wave
velocity (PWV), which is a measure of the velocity of
blood flow in the aorta. The velocity of the pressure wave
is inversely related to vessel elasticity and compliance.
As arteries stiffen, the transmission velocity, commonly
expressed as PWV, increases. PWV also increases as the
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pressure wave travels from the aorta to the periphery,
indicating that vascular compliance is lower in the distal
parts of the arterial tree.
Aortic PWV is considered the ‘gold standard’ measure-
ment of arterial stiffness, as the thoracic and abdominal
aorta makes the largest contribution to arterial buffering
actions, and aortic PWV is an established independent
predictor of outcome1. Arterial stiffness, assessed by mea-
suring aortic PWV, is an independent predictor of cardio-
vascular mortality and morbidity in hypertension, Type-2
diabetes and end-stage renal failure1. In a meta-analysis
of over 17 000 participants, aortic PWV reclassified risk
and improved model fit for future cardiovascular events,
even after accounting for standard risk factors3.
However, the carotid-femoral pathway is commonly
used as a pragmatic surrogate for the aortic system
as it covers the region that exhibits the greatest
age-related stiffening4, and both arteries are superficial
and easy to palpate. The 2011 European Society
of Hypertension guidelines suggest that, in arterial
hypertension, carotid-femoral PWV over 10m/s relates
to subclinical organ damage and cardiovascular events5.
There are no reported normal limits for PWV in
pregnancy, although <10m/s is within the range for
healthy non-pregnant women6. PWV has been reported
to increase significantly with maternal weight and age,
but not with parity or smoking status7.
PWV measurement techniques and devices
PWV is calculated by measuring the transit time (t)
taken for a pressure pulse to travel between two set
points; for carotid-femoral PWV, it is measured from
the common carotid artery to the ipsilateral femoral
artery. Although direct carotid-femoral measurements
are preferred, this may not always be feasible. Several
non-invasive devices derive the distance (d) covered by
the pulse wave approximated to surface distance between
two marked sites. PWV is calculated as: d (in meters)
/t (in seconds). Figure 1 illustrates the foot-to-foot
measurement of carotid-femoral PWV (with ‘foot’ of pulse
wave defined at the end of diastole).
Measurement of distance is relatively simple with the
use of a ruler or measuring tape, although the site (e.g.
measuring the carotid wave at or above the sternal notch)
should always be standardized for all tests within a cohort.
In pregnancy, it is advisable to use metal calipers rather
than tape measure due to the distortion of linear distance
measurements by the shape of the pregnant uterus.
To measure time delay between pressure waveforms
(t), there is a variety of devices utilizing computerized
oscillometry6, applanation tonometry8, Doppler9 or
mechanotransducers10. There is no consensus regarding
which method or device is most valid11,12, and most,
due to their non-invasive nature, are suitable for
use in pregnancy. Most devices have been validated
against invasive testing in non-pregnant cohorts, but not
in pregnancy13–15. Incremental increases in distending
pressure, as represented by mean arterial pressure (MAP),
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Figure 1 ‘Foot-to-foot’ measurement of carotid-femoral pulse-wave
velocity (PWV).
increase PWV; therefore, MAP levels should be taken into
account when comparing groups16. The effect of heart rate
is less clear but this may also be a confounding factor16.
The Complior System (Alam Medical), based on the
piezoelectric principle, uses skin mechanotransducers to
detect simultaneously in two different arteries or at two
different sites waveformswhich can be visualized onscreen
by the operator. Once waveforms of sufficient quality are
recorded, the t between the pressure waveforms at each
site is calculated using a correlation algorithm on the
initial pulse rise to just after true pulse peak, and PWV is
calculated.
Pressure waves can also be recorded sequentially at
different sites, andt calculated from a simultaneous elec-
trocardiographic (ECG) recording. The SphygmoCor
system (AtCor Medical), a device with moderate
reproducibility17, uses high-fidelity applanation tonome-
try to obtain successive proximal and distal pulses a short
time apart. t is then determined as the time difference
of the ECG R-wave in relation to the distal and proxi-
mal pulses. As the measurements are a short time apart,
changes in heart rate variability have minimal effect ont.
The Arteriograph (Tensiomed) and Vicorder (Skid-
more Medical Ltd) devices use an oscillometric distension
technique to obtain PWV. The Vicorder has not been
validated against invasive testing for pulse-wave analysis;
however, it has been validated against the SphygmoCor
and shows good agreement of aortic PWV values, albeit
with an inherent bias towards lower Vicorder aortic PWV
values at higher values of SphygmoCor aortic PWV18.
When using the Vicorder, a pad that inflates over several
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centimeters is placed around the patient’s neck, and a
cuff is placed around the patient’s upper right thigh. Both
carotid and femoral cuffs are inflated to 65mmHg and
the corresponding oscillometric signal from each cuff is
obtained in real time. Once the operator is satisfied with
the waveform quality, the test is terminated and an algo-
rithm of the two waveforms is analyzed to produce t.
The Arteriograph is based on plethysmography and
registers pulsatile pressure changes in an artery. Typically,
upper-arm blood pressure is first measured using a cuff,
which is inflated to at least 35mmHg above systolic
pressure, and brachial artery pressure fluctuations are
analyzed. The difference in time between the beginning of
the first wave and the beginning of the second (reflected)
wave is related to a measured distance from the jugular
notch to the pubic symphysis, allowing calculation of
the PWV.
ARTERIAL WAVE REFLECTION
Another surrogate measure of arterial stiffness is the
arterial pressure waveform, which is a composite of
a forward-traveling wave generated by left ventricular
ejection, and a backward-traveling reflected wave arising
from sites of impedance mismatch, such as arterial taper
and major arterial bifurcations. The change in impedance
is thought to generate wave reflections, similar to the
effect when a stone is dropped into a small pond and
waves hitting the pond edge are reflected back towards
the center, that summate to form a single effective reflected
wave that flows back into the ascending aorta early in the
cardiac cycle.
As arterial compliance decreases, the speed of travel of
the wave increases. This means that the reflected wave
superimposes on the advancing pulse wave at an earlier
time, increasing the amplitude of the forward wave; in
other words, augmenting the systolic pressure wave. This
can be quantified using the augmentation index (AIx),
which is the ratio of the pressure difference (amplitude
difference between the start of a first wave, P1, and the
start of a second reflected wave, P2) in relation to the pulse
pressure, usually expressed as a percentage (Figure 2).
While PWV reflects aortic stiffness, AIx is to some
extent determined by endothelial dysfunction and arterial
resistance, and is thought to be a more sensitive early
marker of arterial stiffness19. Central AIx has been shown
to be an independent predictor of all-cause mortality in
patients with end-stage renal disease or hypertension20,21.
AIx increases linearly with age until 50–60 years, when it
plateaus8,22.
AIx measurement and devices
AIx should be analyzed in the ascending aorta, whichmost
accurately represents the ventricular afterload imposed
by central large arterial walls. However, it is difficult
to obtain direct measurements from central arteries;
therefore, AIx is commonly estimated from either the
radial or the brachial artery waveform. Using a validated
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Figure 2 The arterial waveform complex.
transfer function, an aortic pressure waveform is then
calculated from the peripheral arterial waveform. AIx
increases with MAP and is inversely related to heart
rate and body height, so these variables should be taken
into account when interpreting results. Commonly, AIx
is standardized to a heart rate of 75 bpm (AIx-75). In
pregnancy, maternal ethnicity, smoking, parity, body
mass index and mean uterine artery pulsatility index were
found not to be significant predictors of AIx-7523.
The most widely used approach is to perform
tonometry in the upper limb, usually in the radial artery,
with a high-fidelity probe such as the Millar strain
gauge transducer (SPT-301, Millar Instruments, Sydney,
Australia). The pressure waveform is then transformed
using a transfer function17 (SphygmoCor) to calculate
the aortic AIx. Alternatively, carotid tonometry can be
used. For this, a transfer function is not necessary as the
arterial sites are quite close and the observed waveforms
are similar. However, carotid tonometry requires more
technical expertise, so there is more room for operator
error, especially in obese patients in whom the carotid
artery may be more difficult to palpate. While AIx is
a relative measurement and can be calculated without
calibration, its components (central pulse, heart rate,
augmentation and systolic blood pressure) are absolute
values and require calibration1.
Oscillometric devices such as the Vicorder and
Arteriograph (as described above) can also be used to
analyze pressure waveforms. Brachial artery waveforms
are obtained using a fluid distension technique via cuff
inflation on the upper arm. Similar to tonometry, these
waveforms are then transformed by a transfer function to
produce aortic AIx. There have been no comparative
studies between Vicorder and tonometry in pregnant
women. In a non-pregnant cohort of chronic obstructive
pulmonary disease patients, Vicorder AIx measurements
correlated significantly with SphygmoCor ones; however,
the limits of agreement were only −10.42 to 9.02%,
with a coefficient of reproducibility of 27.9%24. Vicorder
values were lower but there was satisfactory agreement24.
The Arteriograph obtains AIx by calculating the
pressure difference (amplitude difference between the
start of a first wave, P1, and the start of a second reflected
Copyright  2017 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 50: 324–331.
Expert Consensus 327
Table 1 Devices for measuring arterial stiffness (pulse-wave velocity (PWV) and augmentation index (AIx))
Technique/Device Advantages Disadvantages
Mechanotransducer
Complior
(Alam Medical, Pantin, France)
Widely used in first few epidemiological
studies that demonstrated predictive
value of PWV in CVDs
Simultaneous recording of central and
peripheral signal
Portable device
Errors associated with distance
estimation signal
Oscillometric fluid distension
Arteriograph
(Tensiomed, Budapest, Hungary)
Vicorder
(Skidmore Medical Ltd, Bristol, UK)
Affordable
Non-invasive
Good intraobserver variability
Can obtain AIx and central systolic BP
Vicorder not yet validated against
invasive techniques for arterial
function testing
Tonometry
SphygmoCor
(AtCor Medical, Sydney, Australia)
Used in many large observational
studies linking arterial function to
cardiovascular events
Expensive
Measured distance is an estimation of
true distance and largely depends on
body habitus
Omron HEM-9000AI
(Omron Healthcare, Kyoto, Japan)
Similar to SphygmoCor and can obtain
AIx and central systolic BP
Portable
Cannot obtain carotid-femoral PWV
Ultrasound Can analyze waveforms simultaneously
or separately using ECG
synchronization
Requires extensive training
User-dependent variability
Photoplethysmography
PulseTrace PCA 2 and
PulseTracePWV
(Micro Medical, Bournemouth, UK)
More suitable for use in overweight
populations
Only gives information on waveforms at
peripheral body sites; information on
central arterial waveforms less reliable
Inferior quality of waveform obtained
from finger probe
Cardioankle vascular index
VaSera System
(Fukuda Denshi, Tokyo, Japan)
Records distensibility of whole
aortic-iliac, femoral-tibial system
Needs further validation process in
comparison to carotid-femoral PWV
All devices tabulated are non-invasive, and none has been validated against invasive techniques in pregnancy. BP, blood pressure;
CVD, cardiovascular disorder; ECG, electrocardiograph.
wave, P2) in relation to the pulse pressure. The brachial
artery waveform readings allow AIx calculation as: AIx
(%)= ((P2 − P1)/PP)×100, where PP is pulse pressure,
and thus provides the brachial artery AIx without
applying a transfer function. Similar to the Vicorder,
there are no validation studies of the Arteriograph in
pregnancy; however, it has been used widely in pregnancy
research7,25,26 and validated against aortic AIx obtained
by cardiac catheterization in a non-pregnant cohort13.
The advantages and disadvantages of commonly used
devices for recording PWV and AIx are presented in
Table 1.
ENDOTHELIAL FUNCTION
The endothelium lines the internal surface of arteries and
is sensitive to changes in hemodynamic signals, responding
by releasing a number of vasodilator substances, the most
potent of which is nitric oxide (NO), or vasoconstrictors.
Endothelial injury with resulting dysfunction is associated
with atherosclerosis and cardiovascular events27.
Endothelial function is commonly assessed by mea-
surement of upper-arm flow-mediated dilatation (FMD)
or forearm blood flow; although there is no consensus as
to which technique provides more precise information,
forearm blood flow measurement is generally considered
the ‘gold standard’ for endothelial function testing (see
Table 2 for a comparison of their advantages and disad-
vantages). Brachial artery FMD correlates with measures
of coronary endothelial function28,29. Normal arteries
dilate by 10–15% depending on the position of the cuff
and equipment used30. By definition, if vasodilation does
not reach 5%, there is overt endothelial dysfunction29,30.
Flow-mediated dilatation (FMD) measurement
FMD measurement as described by Celermajer et al.30
has been used extensively, with good reproducibility and
low interobserver variability31. This technique requires an
ultrasound system equipped with a high-frequency linear
vascular probe, vascular software for two-dimensional
and color Doppler imaging, and an internal ECG
monitor so that each image frame of blood flow can
be synchronized to the cardiac cycle. A stereotactic
probe-holding device will limit measurement error due
to micromovements of the probe by the operator.
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Table 2 Techniques for measuring endothelial function
Technique Advantages Disadvantages
Flow-mediated dilatation Non-intrusive
Predicts outcome
Relatively quick assessment
Considered a less precise method of assessment
Expensive collateral equipment
Forearm blood flow Currently gold standard
Allows assessment of basal nitric oxide
Strong correlation with cardiovascular outcome
Intrusive
Requires specialist research setting
Time-consuming
With the subject lying supine, a baseline longitudinal
image of the brachial artery with clear visualization of
the anterior and posterior intimal interfaces between
the lumen and vessel wall is first acquired. Then,
arterial occlusion is created using a forearm blood
pressure cuff inflated to suprasystolic pressure for a
standardized length of time. Subsequent cuff deflation
induces a brief high-flow state through the brachial artery
(reactive hyperemia) and the resulting increase in shear
stress causes endothelium-dependent vasodilation. The
longitudinal image of the artery is recorded continuously,
from 30 s before to 2min after cuff deflation. This
continuous imaging period should be sufficient to
capture peak arterial dilatation, which is reported to
occur around 57±15 s after cuff deflation in pregnant
women32,33. At least 10min of rest is needed after
reactive hyperemia before another image is acquired to
reflect the reestablished baseline conditions.
If the endothelium-independent vasodilation response
is to be tested, an exogenous NO donor (usually
nitroglycerin (glyceryl trinitrate, GTN) spray or sub-
lingual tablet) is administered prior to the steps
above, to determine the maximum obtainable vasodila-
tor response 3–4min after GTN administration. The
observed endothelium-independent vasodilation reflects
vascular smooth-muscle function.
FMD is calculated as the percentage change from the
baseline diameter to the peak diameter in response to
reactive hyperemia, using the following equation:
FMD (%) =
((
peak diameter–baseline diameter
)
/baseline diameter
)
× 100.
Forearm blood flow measurement
Resistance vessel function in the forearm is assessed by
strain-gauge venous impedance plethysmography. This
works on the principle that if venous return from the arm
is obstructed and arterial inflow continues unimpeded,
the forearm swells at a rate proportional to the rate
of arterial inflow34. This procedure is generally carried
out as follows: a wrist cuff is inflated to suprasystolic
pressure and 60 s allowed to elapse before measurements
commence. A second cuff is placed around the upper arm
and inflated to around 40mmHg (higher than venous
pressure but lower than diastolic pressure) at intervals of
10 s with 5-s deflation, allowing venous emptying whilst
not impeding arterial inflow. The arms are positioned
above the heart using pads and cushions. A strain
gauge is placed around the forearm and the changes in
circumference (which reflect changes in forearm volume)
are measured.
This test is most useful when comparing dose–response
relationships of different drugs within a single study;
however, drawbacks include reproducibility (due to
variations in arterial pressure, initial forearm blood flow
and forearm size) and the technique’s more intrusive
nature compared with FMD.
ARTERIAL FUNCTION STUDIES IN
PREGNANCY
In normal pregnancy, there is a significant reduction in
unadjusted aortic PWV from preconception to the second
trimester (although the reduction is not significant for
MAP-adjusted PWV). Unadjusted aortic PWV remains
low or increases slightly in the third trimester and returns
to baseline in the postpartum period35,36. Aortic AIx
adjusted for heart rate (i.e. AIx-75) in normal pregnancy
follows a pattern similar to that of aortic PWV, with
the most significant changes occurring between prepreg-
nancy and the early first trimester37. FMD increases
in pregnancy until 32weeks’ gestation, then decreases
significantly from 36weeks38,39.
Studies of arterial stiffness in complicated pregnancies
have focused largely on pre-eclampsia, intrauterine
growth restriction (IUGR), preterm birth and gestational
diabetes (GDM)7,26,40,41, disorders that are associated
with a greater risk of a future cardiovascular event in the
mother.
Arterial function in hypertensive disorders of pregnancy
All parameters of arterial stiffness have been found to
differ significantly in pre-eclamptic women from those in
normotensive pregnancies. In a systematic review of 23
studies evaluating the effect of pre-eclampsia on arterial
stiffness, womenwith pre-eclampsia had increased arterial
stiffness both during and after pregnancy, and to a greater
extent than did women with gestational hypertension.
More severe presentation of pre-eclampsia was associated
with a greater degree of arterial stiffness42. It should be
noted, however, that only a few of the studies included
in the review adjusted arterial stiffness measurements for
the important variables of maternal heart rate or blood
pressure. Significantly higher levels of aortic PWV and AIx
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have also been observed in the subclinical stage (as early as
11weeks’ gestation) of pre-eclampsia23,41; interestingly,
themagnitude of aortic PWV increase in these early phases
was similar to that seen in established pre-eclampsia.
Cross-sectional and longitudinal studies that assessed
arterial stiffness in the early subclinical stages have
demonstrated the potential for indices of arterial stiffness
as a screening test to predict subsequent development
of early- and late-onset pre-eclampsia, especially when
combined with other maternal variables, such as central
systolic blood pressure7,41.
Lower FMD has been found in the first and second
trimesters in high-risk women who subsequently develop
pre-eclampsia, compared with controls43,44. An increase
in FMD has been observed 4–6weeks postpartum in
women who had pre-eclampsia, suggesting partial rever-
sal of the endothelial dysfunction45. Very few studies
of endothelial function in pregnancy have included
both endothelial-dependent and endothelial-independent
measurements; this may affect findings, as both processes
are intricately related and vary considerably during
pregnancy19.
ARTERIAL FUNCTION IN FETAL
GROWTH RESTRICTION
Very few studies have examined aortic PWV in
isolated IUGR. In one study which reported on
small-for-gestational-age (SGA) babies (i.e. a heteroge-
neous cohort of fetuses which were small, some of which
were not growing well (IUGR) and others that were con-
stitutionally small but healthy and growing normally), no
differences were found in aortic PWV recorded in the first
trimester46. In normal pregnancies, a relationship was
found between aortic PWV in the third trimester and birth
weight, with an increase of 1m/s in aortic PWV associated
with a decrease in birth-weight centile of 17.6%47. In
pregnant women with chronic hypertension who subse-
quently developed both superimposed pre-eclampsia and
IUGR, aortic AIx-75 was a determinant of birth weight,
and was the only significantly elevated hemodynamic
parameter in patients who developed IUGR but not
superimposed pre-eclampsia48. Aortic AIx, while normal
in women with normotensive SGA pregnancies, was ele-
vated in women who later presented with pre-eclampsia
and SGA fetuses. In postnatal women whose pregnancies
were affected by IUGR, there was a persistent difference
in FMD compared with controls49. This difference was
not seen when comparing GTN responsiveness between
the two groups, suggesting that the differences in FMD
were due to endothelial rather than vascular smooth
muscle dysfunction.
Arterial function in diabetes in pregnancy
Arterial stiffness indices are higher in women with
established GDM and in those with pre-existing Type-2,
but not Type-1, diabetes mellitus50,51. Furthermore,
women who develop GDM have increased arterial
stiffness which is evident from the first trimester of preg-
nancy, suggesting its potential predictive value26. Possible
mechanisms to explain these associations include: (1)
alterations in the composition of the extracellular matrix
and arterial remodeling, due to hyperglycemia, and (2)
oxidative stress, both of which lead to arterial stiffening.
Additionally, diabetes is associated with reduced NO
production, which may impair endothelial function.
RECOMMENDATIONS FOR ASSESSING
ARTERIAL FUNCTION IN PREGNANCY
• Due to the rapid responses of sympathetic activity and
the arterial system to internal and external influences,
as many variables as possible should be standardized
across all tests.
• Before any measurements are performed, time should
be allowed for adequate acclimatization to the room
in which the tests are to be carried out. In general,
participants should rest in the position in which the
tests are to be carried out (e.g. supine or sitting) for
at least 5min before the tests commence. For FMD
measurements, a resting position of around 20min is
recommended52.
• Room temperature should be set at approximately
22–24 ◦C to control for orthostatic changes. As several
medications that are commonly taken in pregnancy can
affect arterial function, it is generally recommended
that participants refrain from taking such medication
for at least four half-lives of the drug prior to testing,
when possible and safe to do so. Drug and vitamin
intake over the previous 24 h should be recorded and
correlated to the results.
• It is recommended that participants abstain from
caffeinated drinks for at least 4 h and smoking for
12 h prior to hemodynamic testing.
• In pregnancy, caval compression from the weight of
the gravid uterus can affect maternal hemodynamics,
so it is recommended that tests are carried out with
the woman in the left lateral position. If longitudinal
studies are to be performed, this position should also
be standard even when the woman is not pregnant or
in the first trimester.
• Comparison of results should also be adjusted for any
neurohormonal perturbations associated with preg-
nancy and fertility; for example, phase of menstrual
cycle when performing preconception studies or breast-
feeding when performing postpartum assessments. Par-
ticipants who have undergone hormonal stimulation,
such as follicular priming in preparation for in-vitro
fertilization, may have very different hemodynamics53,
and this should be taken into account when comparing
them against women with spontaneous conception.
RECOMMENDATIONS FOR FUTURE
RESEARCH
• Arterial function testing in pregnancy has focused
largely on identifying different hemodynamic signatures
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in pathological pregnancies. More large-scale studies
are needed to assess and validate the role of
arterial function parameters in predicting pregnancy
complications, as well as assessing its prognostic value,
whether alone or in combination with other biophysical
and biochemical markers of metabolic dysfunction.
• Additionally, an understanding of arterial function
changes between preconception and very early preg-
nancy in relation to pathological pregnancy is lacking,
so longitudinal preconception work is needed.
• A few studies54,55 in pregnancy have assessed the impact
of therapy on arterial function, but larger-scale studies
would be helpful in evaluating how and to what extent
the maternal arterial system responds, and whether
treatment options can be adjusted to optimize clinical
outcome.
• To improve our understanding of changes in arterial
stiffness independent of confounding factors, such as
maternal heart rate or blood pressure, which can
change significantly in disorders such as pre-eclampsia,
studies should report appropriately adjusted parameters
alongside raw data.
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